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Consumer attitudes towards direct advertising of prescription drugs – a 
UK perspective
Introduction
The pharmaceutical industry is one of the world’s most dynamic market sectors. The 
investment in research and development is considerable and the risks associated with any 
new product are extremely high. In addition it is a market highly regulated in most countries 
in the world.
From a marketing perspective the industry can be segmented, albeit not precisely, into those 
drugs freely available for sale ‘over the counter’ (OTC) and those that may only be obtained 
by prescription. OTC drugs are offered for self-medication purposes with or without the 
recommendation of health professionals (Hester 2005). Prescription drugs, however, can only 
be obtained with a prescription issued by a physician or certain other healthcare practitioners 
and only dispensed by registered pharmacists (Keynote 2008). According to Datamonitor 
(2009) the global market for prescription drugs is $644bn with $187bn of that from Europe. 
The UK market was estimated at $25.7bn and forecast to rise to $28bn by 2014.
Prescription drug marketing like tobacco and alcohol, are seen as controversial and even a 
“taboo” until quite recently (Huh et al 2006, Cox and Cox 2010). There is much controversy 
surrounding DTCA of prescription drugs but despite this, advertising budgets continue to 
grow (Mehta and Purvis 2003).
In the UK, the advertising of prescription drugs is regulated by a combination of domestic 
and European regulation (MHRA 2005). Prescription drugs can only be promoted to 
physicians or other healthcare professionals and not to the public at large (ABPI 2010). In the 
UK, as in the rest of the European Union, only non-prescription (or OTC) drugs can be 
advertised direct to the public. Although there is a general ban each jurisdiction interprets the 
level of restriction. In the UK, for example, disease awareness campaigns sponsored by 
pharmaceutical manufacturers are allowable under the regulations, but not the promotion of  
individual prescription brands 
DTCA drug advertising – evidence from the US and NZ
In only two regulated markets in the world is direct to the consumer advertising (DTCA) of 
prescription drugs permitted. Legislation in the United States of America and New Zealand 
legislation is interpreted such that it does not inhibit (as opposed to specifically allow) the 
advertising of prescription drugs. In the US it emerged in the early 1980s as a result of a 
regulatory loophole (Hoek and Maubach 2005) when legislation introduced in 1969 was 
challenged as contrary to the First Amendment which stated “Congress shall make no law 
prohibiting freedom of speech”. The first product-specific prescription advertisement was 
released by Boots Pharmaceuticals, the US subsidiary of Boots UK and quickly followed by 
other producers including Merck, Sharp and Dohme and Eli Lilly. The US Food and Drug 
Administration (FDA) had nominal jurisdiction in this field but rather than try to oppose it 
the FDA called on the industry to impose a voluntary moratorium while they studied 
consumer reaction. Several studies were undertaken. One suggested US consumers wanted 
more information about prescription drugs whilst another concluded that consumers retained 
more information about drug benefits than risks (Palumbo and Mullins 2002). In 1985 the 
FDA lifted the moratorium determining that DTCA of prescription drugs were allowable 
provided they met the same standards applicable to advertisements targeted at physicians. In 
New Zealand the introduction of the 1990 Human Rights Bill’s freedom of speech legislation 
was interpreted as removing barriers to the advertising of prescription drugs. Given the new 
regulatory framework pharmaceutical companies perceived NZ legislation as being 
analogous to the US Constitution and proceeded to introduce DCTA (Wolf 2002). As in the 
US, NZ regulators did not predict how quickly DTCA of prescription drugs would spread. 
Research has been more limited than in the USA. Nevertheless Hoek et al (2003)  conducted 
a national survey which enabled a comparison to be made with the FDA surveys made 
around the same time (see figure 1). This comparison showed that over 40% of New 
Zealanders were concerned that DTCA would affect their relationships with their doctors and 
two-thirds doubted it would improve discussion with physicians. US consumers were 
significantly less pessimistic. In both countries significant numbers of consumers believed 
DTCA inflated the drugs benefits and even more wanted more information on the risks and 
side effects. Over half of New Zealanders felt it would improve health decision-making 
whereas in the US it was around a third. In both countries, however, the large majority of 
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Figure 1 US and NZ Consumers' attitudes towards DTCA 
Both US and NZ pharmaceutical companies took the view that explicit, DTCA would benefit 
sales. By 2009 $4.3bn was being spent in the US on DTCA an average of over $50m per drug 
(IMS Health 2010). Although a considerably smaller market, New Zealand DTC prescription 
drug advertising expenditure has also grown rapidly from $11.6m in 1999 to $38m by 2004 
(Hoek 2008). Research in both countries suggest that this promotional effort may pay off. 
Metzi (2007) reports that DTCA has changed how patients and physicians interact. In over 
40% of cases where patients request an advertised drug a prescription for it is issued.
In Europe a proposal to allow pharmaceutical companies to advertise products associated 
with a limited number of health conditions was rejected by the European Parliament in 2002 
(Auton 2004). According to Eagle and Kitchen (2002), however, the experience of the US 
and NZ provide a foundation for informed debate. The discussion that has taken place has 
tended to be at the health industry level. 
Benefits of DTCA of prescription drugs
Proponents of DTCA of prescription drugs claim it encourages individuals to seek advice for 
undiagnosed symptoms (Berndt 2005), “is an excellent way to meet the demand for medical 
information, empowering consumers by education about health conditions and possible 
treatments” (Holmer 1999) or that it empowers patients to take a more proactive role in their 
healthcare by promoting more informed patient-physician discussion (Mehta and Purvis 
2003, Spake and Joseph 2007). Opponents note that such promotion is no better than that of 
fast-moving consumer goods (Toop and Richards 2003) despite the product’s complexity and 
potential side-effects. Consumers may not fully comprehend the risks associated with a 
drug’s use (Mehta and Purvis 2003). The claim is also made that benefit-based advertising 
may potentially lead to consumer pressure based on false expectation rather than rational 
diagnosis (Lexchin and Mintzez 2002) and impact the patient physician relationship (Hollon 
1999). Currently European governments tend to give more credence to those negative effects 
on society’s welfare (Fiscer and Albers 2010). Major European bodies such as the UK 
Consumers Association, Amsterdam-based Health Action International and Brussels-based 
Bureau Européen de Unions de Consummateurs actively oppose direct to consumer 
advertising although some, including the UK Patients Association, take a broadly supportive 
stance of awareness campaigns if they remain unbranded (Reast et al 2008). In the case of the 
UK Consumers Association their opposition was supported by a survey which suggested only 
25% of respondents believed that drug manufacturers would provide unbiased and reliable 
information (Reast et al 2004). UK physicians, meanwhile, have, in surveys conducted over 
the past 10 years, consistently opposed DCTA of prescription drugs (Reast and Carson 2000, 
Reast et al 2004, Reast et al 2008) perhaps because it is perceived to give drug companies 
influence in the patient-doctor relationship (Huh and Becker 2005). Knowledge of the 
public’s appreciation of the issues surrounding DTCA is still, however, poor (Hoek 2008) 
and there has been little independent consumer-based research probably owing to its current 
prohibition (Reast et al 2008). This research, therefore, seeks to throw light on the UK 
consumers attitudes to the promotion of prescription drugs.
    
Methodology
This research seeks to shed light on the UK consumer’s attitude to DTCA of prescription 
drugs relating to the future relaxation of legislation in the UK. It does not seek to measure 
support or opposition at the current time per se. Rather it is looking to establish those issues 
that are paramount in consumers’ minds relative to such a change. The research objectives 
developed therefore are:
• To explore consumer attitudes towards direct to consumer advertising of prescription 
drugs
• To investigate consumer reactions to TV and press advertisements from the US and 
NZ
• To identify areas of resistance to DTCA among consumers.
The philosophy underpinning this research is an interpretivist one in that the social reality is 
subjective and shaped by perceptions (Creswell 1994). It will utilise qualitative techniques to 
draw results from empirical observation. As there is little research about the UK context it 
should be seen as an exploratory study which seeks to looks for patterns of meaning rather 
than the testing of hypotheses (Collis and Hussey 2009). A total of 16 in-depth interviews 
took place and a further 12 respondents took part in two focus groups. The decision to use 
both individual issues and focus groups was made to establish whether, in the latter, society-
based pressures may give rise to issues that might not be forthcoming in one-to-one 
interviews. Non-probability, convenience sampling was used, however, given the nature of 
the research a broad representation of ages and balance of genders was achieved albeit with 
geographical limitations. The focus groups were segregated by age with participant in the 
first ranging from 20 to 35 years of age and the second from 45 to 70 years. This contrasted 
with most US and NZ research on DTCA which focused on consumers over 35 although 
younger consumers are just as likely to be exposed through mass media (Baca et al 2005). 
The group dynamics were ordered by a moderator using a previously prepared interview 
guide (Morgan 1998). As consumers would not, in the ordinary course of events have been 
exposed to DTCA television advertisements and press advertising from the USA and NZ 
were available for viewing prior to the interviews and focus groups.
The researcher complied with the ICC/ESOMAR International Code on Market and Social 
Research 2007 (Esomar 2007).
Findings
The findings of this study suggested that, although there were areas of general agreement, 
there were a number of disparities between consumers of both age groups and amongst 
interviewees and focus groups. Having been shown advertising emanating from the US and 
NZ (on products also available in the UK) there was more concern on the cultural approaches 
to advertising than the products themselves. As one interviewee noted about one US example 
‘those advertisements are too American’. As regards content the majority of younger 
respondents saw limitations in the claim that this type of advertising offers health education 
whereas older respondents were generally more positive. In general younger participants felt 
these advertisements attempted to give too much information leading to confusion whereas 
older consumers were less complaining about style and content. Many younger participants 
felt the advertising played upon fear. As one noted it ‘tries to manipulate people’s emotions’. 
Older respondents in general believed that this advertising was presented in a reasonably 
responsible way. Despite a general negativity in relation to the advertising, particularly 
amongst the younger age groups, most respondents believed that DTCA (presumably 
formatted to UK cultural norms) could provide information that would empower the 
consumer. The exception to this was amongst members of the older focus group who felt 
much of this advertising would be too technical and confuse consumers by providing too 
much information. Attitudes regarding providing information on side-effects in both age 
groups were mixed. Some felt it important that there be a balance of information between 
potential benefits and downsides whereas others believed this, in the words of one 
respondent, ‘put them right off’.  There was general agreement that DTCA of prescription 
drugs could prompt early diagnosis of a medical decision and as a reminder to adhere to 
existing drug therapy. However, there was discussion amongst older focus group members as 
to whether it would prompt many hypochondriacs to seek unnecessary help and waste their 
doctor’s time. There was general agreement among participants that such advertising 
mitigated against the stigma attached to certain conditions (i.e. sexual dysfunction). As one 
focus group member noted ‘this kind of information can act to reduce misconceptions and to 
improve communications’. The majority of respondents believed that, having been exposed 
to DTCA, they would be likely to ask for a drug by its brand name although there was 
general agreement that even branded drug names were confusing. However, the suggestion 
that a UK consumer ask a doctor to prescribe a particular drug did not sit comfortably with 
the majority of respondents. The vast majority of respondents would continue to rely on the 
physician to prescribe the appropriate drugs. Whereas they saw some benefit in being 
empowered in any health discussion, particularly in an introduction, they reported high levels 
of trust in their doctors and saw them as the expert healthcare information providers and not 
the drug companies. This attitude was particularly evident amongst older focus group 
participants who, in general, believed such discussions were a potential cause of conflict and 
a waste of consultation time albeit unlikely to impact on the patient-physician relationship. 
Amongst older participants there were particularly high levels of trust in British physicians. 
Younger participants tended to feel they were held in over-high esteem and were prone to 
patronise but still trusted them to determine the best health care. There was general feeling 
that drug companies were contributing to overall wellbeing and that their spending on 
research was important. On the downside there was a general lack of trust in organisations 
making huge profits through, it was generally perceived, inflated pricing, particularly of 
branded goods.
Summary
This research looked at issues concerning the introduction of DTCA of prescription drugs 
from a UK perspective. The findings highlight concerns regarding the benefits and potential 
threats amongst UK consumers with particular attention to different age groups. There were 
also subtle differences between the attitudes of one-to- one interviewees and those emanating 
from focus groups. In general, considered discussion led to more negativity than in one-to-
one interviews. In relation to previous research in the USA and NZ there were considerably 
higher levels of concern regarding the doctor-patient relationship. In relation to the USA, 
which has considerably less concerns, the emotional attachment in the UK to the National 
Health Service and the equally emotional opposition to ‘socialised medicine’ in the United 
States may, in part, be manifesting itself. In general it was felt that DTCA could promote 
initial discussion but should not dominate it and little support for the proposition that it 
improved health decisions. Again trust in the UK health professional to come to the right 
conclusion was paramount. There were some shared concerns that DTCA over emphasised 
benefits over side effects and relatively general agreement, in line with US/NZ research, on 
the benefits of advertising on promoting new drugs.
This research shows that there is no great demand from consumers to allow DTCA of 
prescription drugs and several deeply held concerns. The branded prescription drug industry 
will, however, continue to push for restrictions to be removed so the lobbying of national and 
supra-national governments will no doubt continue. The internet and, to an extent, satellite 
television, may de facto make the legislation sterile as it has in other areas of marketing (e.g. 
product placement regulations, television advertising regulations). Further research based 
upon this exploratory study may begin to reflect these changes.
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